Abstract 1440P
Background
Apatinib, a selective inhibitor of VEGFR2, showed a synergistic effect when combined with camrelizumab and chemotherapy in advanced esophageal squamous cell carcinoma (ESCC). We aim to assess the efficacy and safety of using the combination of camrelizumab with apatinib and chemotherapy as the neoadjuvant therapy for ESCC.
Methods
Patients with untreated, resectable (stage II or III) ESCC were enrolled. Each patient received two 21-day cycles of neoadjuvant treatment with intravenous camrelizumab, albumin-paclitaxel, carboplatin on day 1, and oral apatinib on days 1-14, followed by the third cycle without apatinib. The primary end point was pathological complete response (PCR). Secondary endpoints included safety, objective response rate (ORR) and disease control rate (DCR).
Results
Between February 2022 and November 2023, 70 eligible patients were enrolled. Three patients discontinued the treatment due to toxicity and 67 patients have completed the full three-cycle treatment. The ORR and DCR were 89.3% and 100%, respectively. 60 (85.7%) patients underwent surgery, and R0 resection was achieved in all cases. PCR was identified in 25 (41.6%) patients, and 5 (8.3%) patients had complete response of the primary tumor but residual disease in lymph nodes alone. Grade 3 or 4 trAEs included neutropenia (57.8%), leukopenia (55.2%), thrombocytopenia (28%), hepatitis (14.2%), febrile neutropenia (12.4%), hypertension (8.6%), and rash (4.2%). The median follow-up was 18.76 months and the 1-year DFS and OS rate was 90% and 95.7%. In prespecified exploratory biomarker analysis, PCR group exhibited elevated infiltrating cytotoxic T cells and effector memory T cells compared to the non-pCR group. Increased abundance of mature tertiary lymphoid structures was associated with PCR.
Conclusions
Neoadjuvant camrelizumab combined with apatinib and chemotherapy in patients with resectable ESCC achieved a high PCR rate (41.6%) and manageable trAEs. Larger cohorts are needed to examine whether this regimen is superior to that of camrelizumab combined with chemotherapy only regarding PCR and long-term survival.
Clinical trial identification
ChiCTR2100051763.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Institutional funding of First Affiliated Hospital of SUMS.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1505P - Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)
Presenter: Anton Lahusen
Session: Poster session 18
1506P - ctDNA testing based on deep NGS predicts treatment efficacy and prognosis in advanced pancreatic cancer patients
Presenter: Tingting You
Session: Poster session 18
1507P - Revolutionizing clinical trials: Harnessing artificial intelligence for optimized phase III studies in pancreatic cancer
Presenter: Marie-Edith Bonneterre
Session: Poster session 18
1509P - Cytokines and ductal pancreatic adenocarcinoma: Exploring their relationship with prognosis and molecular subtypes
Presenter: Laura Gutierrez Sainz
Session: Poster session 18
1510P - Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapy
Presenter: Sai Surendran
Session: Poster session 18
1511P - The influence of intratumoral bacteria and peri-operative antibiotic treatment on the outcome of resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy
Presenter: Steffen Ormanns
Session: Poster session 18
1512P - The role of pancreaticoduodenectomy for octogenarians with pancreatic cancer
Presenter: Keita Sonoda
Session: Poster session 18
1513P - Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)
Presenter: Omali Pitiyarachchi
Session: Poster session 18
1514P - A prospective, single-center, randomized, controlled, evaluator-blinded, feasibility clinical trial for efficacy and safety of a non-tissue destructive compact focused ultrasound system with neoadjuvant FOLFIRINOX in locally advanced or borderline resectable pancreatic cancer
Presenter: Jae Young Lee
Session: Poster session 18